Biotech Values

[DewDiligence]

That's a question people were asking when RVNC reported the BELMONT phase-2 data in 2015.

Increasing the dose of botulinum toxin above the point of saturation does not extend the duration of effect. We saw this in the BELMONT study, where the 60U dose did not produce longer duration than the 40U dose.

Further, investors need to bear in mind that number of "units" in a dose of Botox vs a dose of RT002 are not directly comparable.

p.s. Get ready for a war of word games, as discussed in #msg-136664157.